Cel Sci Corporation (CVM)

[przgwxl]

@ZS: I agree on the stopping criteria. I needed to go deeper. I do think the correct interpretation confirms that the trial would not have been stopped early for efficacy. Is there anything else to be gotten from this view?

For instance, if Cel-Sci/SEER survival statistics are assumed for the control arm, then the hazard ratio now is around 0.5. It was unlikely to be much different last October. If MK is generating that size of effect, why would the trial have not been stopped in October?

On the hazard ratio, I likely mis-computed.

Sorry for all the confusion. I would be interested in the answer to the question, may give a hint of the likely range to treatment effect. I did point to a paper in a previous post that pointed to a very large treatment effect when the ratio of CD4/CD8 leukocytes was adjusted by a treatment, exactly the impact Cel-Sci believes MK would have. I just don't know if this is possible given the results of the interim analyses.

I'd think the IDMC recommendation would be independent of Cel-Sci's desire to continue or stop the trial, so when the IDMC says continue I assume stopping criteria have not been met.